Virios Therapeutics Inc Ordinary Shares VIRI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VIRI is a good fit for your portfolio.
News
-
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
-
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
-
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
-
Virios Therapeutics Shares Rise 52% After FDA Feedback for IMC-1
Trading Information
- Previous Close Price
- $0.44
- Day Range
- $0.40–0.45
- 52-Week Range
- $0.28–2.42
- Bid/Ask
- $0.40 / $0.44
- Market Cap
- $8.20 Mil
- Volume/Avg
- 72,087 / 372,546
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (“FM”) and Long-COVID (“LC”). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.virios.com
Valuation
|
Metric
|
VIRI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.15 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VIRI
|
|---|---|
Quick Ratio | 9.25 |
Current Ratio | 11.62 |
Interest Coverage | — |
Quick Ratio
VIRI
Profitability
|
Metric
|
VIRI
|
|---|---|
Return on Assets (Normalized) | −79.21% |
Return on Equity (Normalized) | −88.03% |
Return on Invested Capital (Normalized) | −90.87% |
Return on Assets
VIRI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mxrrvhxwq | Jvljn | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tlgzzmw | Zdrsst | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hjzvwjvn | Fgpdx | $98.8 Bil | |
MRNA
| Moderna Inc | Rsxfpznyr | Hrnmk | $38.8 Bil | |
ARGX
| argenx SE ADR | Zfcwlddfx | Hqgy | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Kspsfvxly | Gpgrx | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vgfwcknlw | Hpdwhn | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pmcjkzg | Vwdbszb | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ltcjcpgxq | Xgcwpqc | $12.4 Bil | |
INCY
| Incyte Corp | Qwhvpmyj | Vggwdk | $11.9 Bil |